经粘膜给药系统市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00004209
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

【研究报告】经粘膜给药系统市场规模预计将从2023年的802.1亿美元增长到2031年的1294.6亿美元;预计2023年至2031年复合年增长率为6.2%。

分析师观点

经粘膜给药涉及粘膜,如口腔粘膜、鼻粘膜、直肠粘膜、阴道粘膜、眼部粘膜等。用于给药的粘膜和肺粘膜。较高的生物利用度、快速起效、避免首过代谢以及易于给药是该药物递送系统相对于传统给药途径的主要优势。该报告包括由于当前跨粘膜给药系统市场趋势及其在预测期内可预见的影响而产生的增长前景。

推动跨粘膜给药系统市场增长的因素

跨粘膜给药系统是首选由于这种类型的递送具有持续的功效,因此可以采用更有效的给药途径。经粘膜途径,例如鼻内、口腔、舌下和直肠,是全身递送药物的无创方法。它们特别有用,因为护理人员或患者可以在不需要专家人员的情况下施用这些药物。此外,起效快且首过代谢减少,使其成为姑息治疗和临终关怀的理想选择。他们可以快速缓解症状并为患者提供快速缓解。因此,经粘膜递送系统已成为治疗心血管疾病、糖尿病和慢性呼吸道疾病等各种慢性疾病的流行选择。根据 PubMed Central 于 2020 年 1 月发表的一篇文章,进行了一项研究,以调查和比较二氢麦角胺 (DHE) 以鼻内 DHE 粉末 (STS101)、鼻内 DHE 喷雾剂 (Migranal) 形式给药时的安全性和药代动力学。 ),以及健康受试者肌内(IM)DHE注射。该研究得出的结论是,STS101 是一种易于给药、非注射的偏头痛急性治疗方法,具有良好的耐受性。进一步预计它可以促进快速、持续的疼痛缓解,并抑制偏头痛症状而不复发。

许多药物以口腔粘膜形式提供;这些药物包括心血管药物、镇静剂和镇痛剂。可生物降解的口腔膜有助于药物输送至体循环,这对于患有吞咽困难、反复呕吐、高血压、心脏病、哮喘、恶心、瘫痪和精神障碍的个体非常有利。这些口腔速溶薄膜是薄的粘合带,放置在患者的舌头或任何口腔粘膜组织上。

因此,易于给药、高生物利用度、全身药物利用度和快速作用等优点推动了口腔快速溶解薄膜的发展。经粘膜给药系统市场增长。

战略见解

报告细分和范围

“2031 年全球经粘膜给药系统市场分析”是一份专门且深入的报告研究制药行业,特别关注全球市场趋势分析。该报告旨在提供市场概览,并根据系统、最终用户和地理位置进行详细的市场细分。它提供了主要市场参与者的关键统计数据,并提到了市场中普遍存在的主要趋势和机会。全球经粘膜给药系统市场报告的范围涵盖北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、西班牙和欧洲其他地区)、亚太地区(中国、日本、印度、澳大利亚、韩国和亚太地区其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美和中美洲(巴西、阿根廷以及南美和非洲其他地区)中美洲)。

基于系统的见解

根据系统,市场分为鼻肺、口腔和舌下、阴道等。鼻肺细分市场在 2023 年占据最大的经粘膜给药系统市场份额,预计 2023 年至 2031 年复合年增长率最高。

基于最终用户的见解

基于最终用户,市场分为医疗机构、家庭护理机构等。 2023 年,医疗保健设施领域占据了最大的市场份额。这可以归因于医院拥有更好的设施和熟练的医生。此外,预计家庭护理设置领域从 2023 年到 2031 年将保持最高的复合年增长率。

经粘膜给药系统市场,按最终用户划分 - 2023 年和 2031 年

区域分析

根据地理位置,市场主要分为北美、亚太地区、欧洲、中东和非洲以及南美洲和中美洲。就收入而言,2023年北美将占据最大的经粘膜给药系统市场份额。美国在该地区占据主导地位。这可以归因于糖尿病、哮喘和心脏病等慢性病病例的增加,以及主要参与者推出的产品数量的增加。

行业发展和未来机遇:

跨粘膜给药系统市场预测可以帮助该市场的利益相关者规划他们的增长战略。根据公司新闻稿,下面列出了全球市场领先企业的一些战略发展:

2024 年 2 月,Aquestive Therapeutics, Inc. 在美国过敏学会展示了一张海报,哮喘与免疫学 (AAAAI) 2024 年年会在华盛顿特区举行,重点介绍了两项完整的舌下 Anaphylm(肾上腺素)膜临床研究的积极药代动力学 (PK) 和药效 (PD) 数据。 2022 年 8 月,iX Biopharma有限公司推出了 IXB-322,这是一项扩大其产品线的新计划。该项目旨在开发一种舌下含服右美托咪定晶片,用于治疗痴呆症和其他适应症的躁动。该举措是 iX Biopharma 战略的一部分,该战略旨在利用其专有的 WaferiX 药物输送平台技术重新利用现有已批准药物。 2021 年 5 月,日本 Zeria 集团旗下的 Tillotts Pharma AG 在其胃肠病学产品组合中添加了一种新药物,推出 AsacolTM 1g(美沙拉嗪)。高强度栓剂用于治疗成人轻度至中度溃疡性直肠炎症状。此次推出将帮助该公司为胃肠道疾病患者提供创新疗法。 AsacolTM 1g 栓剂为患有溃疡性直肠炎的个体提供了一种方便的治疗方式,因为他们只需要每天服用一次剂量。 2021 年 4 月,Teva Pharmaceutical Industries Ltd. 的美国子公司 Teva Pharmaceuticals USA, Inc. 宣布发布 Casana 1(美沙拉嗪)栓剂仿制药。该药在美国适用于治疗活动性溃疡性直肠炎(溃疡性直肠结肠炎)。梯瓦制药工业有限公司;信诺公司。生物递送科学国际公司; 3M;汉高芬兰公司;葛兰素史克公司;询问疗法公司;卡穆鲁斯AB;西美迪卡;和 Noven Pharmaceuticals, Inc 是跨粘膜给药系统市场报告中介绍的几家主要公司。这些领先企业专注于扩大市场影响力和客户群并使其多元化,挖掘市场商机。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are transmucosal drug delivery systems?

The transmucosal drug delivery involves mucosal membranes such as oral mucosa, nasal mucosa, rectal mucosa, vaginal mucosa, ocular mucosa, and pulmonary mucosa for drug administration. Higher bioavailability, rapid onset of action, evasion of first-pass metabolism, and ease of administration are the key advantages of this drug delivery system over traditional routes of drug administration.

What factors drive the transmucosal drug delivery systems market?

Key factors driving the transmucosal drug delivery systems market growth is rising adoption of drug delivery systems for disease management and the development of new drug molecules and biological formulations.

What was the estimated transmucosal drug delivery systems market size in 2023?

The transmucosal drug delivery systems market was valued at US$ 80.21 billion in 2023.

Who are the major players in the transmucosal drug delivery systems market?

The transmucosal drug delivery systems market majorly consists of the players, including Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finland Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; and Noven Pharmaceuticals, Inc.

What are the growth estimates for the transmucosal drug delivery systems market till 2031?

The transmucosal drug delivery systems market is expected to be valued at US$ 129.46 billion in 2031.

Which system segment dominates the transmucosal drug delivery systems market?

The transmucosal drug delivery systems market, by systems, is bifurcated into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held a larger market share in 2023.

The List of Companies - Transmucosal Drug Delivery Systems Market

  1. Teva Pharmaceutical Industries Ltd
  2. Cigna Corporation
  3. BioDelivery Sciences International, Inc
  4. 3M
  5. Henkel Finland Oy
  6. GlaxoSmithKline plc
  7. Aquestive Therapeutics, Inc
  8. Camurus AB
  9. Ximedica
  10. Noven Pharmaceuticals, Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports